n(4)-hydroxycytidine has been researched along with adenosine monophosphate in 5 studies
| Studies (n(4)-hydroxycytidine) | Trials (n(4)-hydroxycytidine) | Recent Studies (post-2010) (n(4)-hydroxycytidine) | Studies (adenosine monophosphate) | Trials (adenosine monophosphate) | Recent Studies (post-2010) (adenosine monophosphate) |
|---|---|---|---|---|---|
| 42 | 1 | 32 | 11,432 | 257 | 2,798 |
| Protein | Taxonomy | n(4)-hydroxycytidine (IC50) | adenosine monophosphate (IC50) |
|---|---|---|---|
| Fructose-1,6-bisphosphatase 1 | Sus scrofa (pig) | 1.3 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 2.6436 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.6 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.44 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 0.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S | 1 |
| Cherrington, NJ; Ekins, S; McGrath, ME; Miller, SR; Wright, SH; Zorn, KM | 2 |
| André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
| Johnson, EK | 1 |
5 other study(ies) available for n(4)-hydroxycytidine and adenosine monophosphate
| Article | Year |
|---|---|
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication | 2020 |
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Dose-Response Relationship, Drug; Drug Interactions; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; HeLa Cells; Humans; Protein Binding; SARS-CoV-2 | 2021 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
A Comment on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites".
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Cytidine; Humans; Nucleosides; SARS-CoV-2 | 2022 |
Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites".
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Cytidine; Humans; Nucleosides; SARS-CoV-2 | 2022 |